Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17500350 | 0.91 | NPC1 (0.43) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL4841403 | 0.90 | NPC1 (0.42) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL3433024 | 0.88 | HSD17B10 (0.39) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL3499128 | 0.86 | HSD17B10 (0.36) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL28069712 | 0.86 | FABP5 (0.45) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL208874 | 0.85 | FABP5 (0.41) | RAB9AKMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL4784032 | 0.85 | FABP5 (0.41) | RAB9AKMT2AMEN1TSHRFABP5 | |
| SCHEMBL1526171 | 0.84 | FABP5 (0.40) | RAB9AKMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL2990766 | 0.84 | MEN1 (0.43) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL6298094 | 0.84 | FABP5 (0.42) | KMT2AMEN1TSHRHSD17B10FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395829-A1 | COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY | Entrada Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395831-A1 | COMPOSITIONS AND METHODS FOR SKIPPING EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY | Entrada Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-11987821-B2 | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy | ENTRADA THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-20240140992-A1 | HEXADEPSIPEPTIDE COMPOUNDS AND METHODS OF USING THE SAME | LODO THERAPEUTICS CORP (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4358989-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240101509-A1 | NON-PEPTIDIC CELL-PENETRATING MOTIFS | OHIO STATE INNOVATION FOUNDATION | 2024-03-28 | — | — | US | disclosed |
| US-6057122-A | PREPARING KRINGLE PEPTIDES; INCUBATING MAMMALIAN PLASMINOGEN WITH ELASTASE AND ISOLATING KRINGLE PEPTIDES | ABBOTT LABORATORIES (US) | 2000-05-02 | — | — | US | disclosed |
| WO-2000009553-A2 | ANTIMICROBIAL PEPTIDES ISOLATED FROM THE SKIN OF AMERICAN FROGS | BIONEBRASKA, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5981484-A | ADMINISTERING TO A HUMAN IN NEED OF ANTIANGIOGENESIS THERAPY AN EFFECTIVE AMOUNT OF MAMMALIAN KRINGLE 5 PEPTIDE FRAGMENT | ABBOTT LABORATORIES (US) | 1999-11-09 | — | — | US | disclosed |
| US-5972896-A | BIOLOGICAL ANTIGROWTH AGENT | ABBOTT LABORATORIES (US) | 1999-10-26 | — | — | US | disclosed |
| US-5932545-A | PEPTIDES | ABBOTT LABORATORIES (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0918795-A1 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | Abbott Laboratories (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0910571-A2 | NOVEL ANTIANGIOGENIC PEPTIDES, POLYPEPTIDES ENCODING SAME AND METHODS FOR INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998041542-A1 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LABORATORIES (US) | 1998-09-24 | — | — | WO | disclosed |
| WO-1997041824-A2 | ANTIANGIOGENIC PEPTIDES DERIVED FROM PLASMINOGEN | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987821-B2 | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy | PYGB, FPGS, GLS2 | NPC1 536/4885RAB9A 1795/4885KMT2A 3143/4885 |
| US-20240101509-A1 | NON-PEPTIDIC CELL-PENETRATING MOTIFS | TIMM50, TIMM10, PITRM1 | NPC1 302/4885RAB9A 1417/4885KMT2A 4862/4885 |
| US-20240140992-A1 | HEXADEPSIPEPTIDE COMPOUNDS AND METHODS OF USING THE SAME | SLC10A1, DNPEP, IAPP | NPC1 954/4885RAB9A 1274/4885KMT2A 4485/4885 |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | NPC1 1260/4885RAB9A 2090/4885KMT2A 4740/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | NPC1 198/4885RAB9A 925/4885KMT2A 4698/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | NPC1 115/4885RAB9A 1840/4885KMT2A 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.